<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="confer">
            <roleset id="confer.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x09;&#x09;// mechanism, process, entity(imply to condition or property in that entity) // &#x0A;" />
                    <role n="1" descr="given biological property&#x09;&#x0A;" />
                    <role n="2" descr="entity receiving the biological property&#x09;         // gene product, celll, tissue, etc. //&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance can be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance can have been conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance could be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance has been able to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance has been conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is able to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is believed to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is believed to have been conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is observed to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance is shown to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance may be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance may have been conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance might be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was able to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was believed to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was observed to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance was shown to be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance will be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance will have been conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that resistance would be conferred by substitutions at Gly156 and Lys165 to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 are able to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 are believed to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 are observed to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 can confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 conferred resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 could confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 have the ability to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 may confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 may have conferred resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 may have the ability to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 might confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 were able to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 were believed to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 will confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 would confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 would have conferred resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests the ability of substitutions at Gly156 and Lys165 to confer resistance to 06-BG through backbone distortions.</text>
                    <arg n="0">substitutions at Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) conferring resistance to alkylation chemotherapies is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) having conferred resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) that conferred resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) that confers resistance to alkylation chemotherapies is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) that has conferred resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which can confer resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which conferred resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which confers resistance to alkylation chemotherapies is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which has conferred resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which is able to confer resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which is believed to confer resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which is observed to confer resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) which may confer resistance to alkylation chemotherapies was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, can confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, conferred resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, could confer resistance to alkylation chemotherapies and was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, has the ability to confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is able to confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is believed to confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, is observed to confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, may confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, might confer resistance to alkylation chemotherapies and was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was able to confer resistance to alkylation chemotherapies and was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was believed to confer resistance to alkylation chemotherapies and was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, was observed to confer resistance to alkylation chemotherapies and was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, will confer resistance to alkylation chemotherapies and is therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, would confer resistance to alkylation chemotherapies and was therefore an active anticancer drug target.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>In addition, EvgA overexpression can not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>In addition, EvgA overexpression could not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>In addition, EvgA overexpression does not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>In addition, EvgA overexpression has not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>In addition, EvgA overexpression is not able to confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>In addition, EvgA overexpression may not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>In addition, EvgA overexpression might not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>In addition, EvgA overexpression was not able to confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>In addition, EvgA overexpression will not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>In addition, EvgA overexpression would not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>In addition, loss-of-function mutations are not conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>In addition, loss-of-function mutations can not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>In addition, loss-of-function mutations can not have been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>In addition, loss-of-function mutations could not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>In addition, loss-of-function mutations have not been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>In addition, loss-of-function mutations is believed not to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>In addition, loss-of-function mutations is observed not to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>In addition, loss-of-function mutations may not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>In addition, loss-of-function mutations may not have been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>In addition, loss-of-function mutations might not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>In addition, loss-of-function mutations was believed not to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In addition, loss-of-function mutations was observed not to be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>In addition, loss-of-function mutations were not conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>In addition, loss-of-function mutations will not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>In addition, loss-of-function mutations will not have been conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>In addition, loss-of-function mutations would not be conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>In itself, an increased risk of diabetes cannot be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>In itself, an increased risk of diabetes could not be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>In itself, an increased risk of diabetes is believed not to be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>In itself, an increased risk of diabetes is not able to be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>In itself, an increased risk of diabetes is not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>In itself, an increased risk of diabetes may not be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>In itself, an increased risk of diabetes may not have been conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>In itself, an increased risk of diabetes might not be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>In itself, an increased risk of diabetes was believed not to be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>In itself, an increased risk of diabetes was not able to be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>In itself, an increased risk of diabetes was not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>In itself, an increased risk of diabetes will not be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>In itself, an increased risk of diabetes will not have been conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>In itself, an increased risk of diabetes would not be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>In itself, the gene variant cannot confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>In itself, the gene variant cannot have conferred an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>In itself, the gene variant could not confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>In itself, the gene variant did not confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>In itself, the gene variant is believed not to confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>In itself, the gene variant is not able to confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>In itself, the gene variant may not confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>In itself, the gene variant may not have conferred an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>In itself, the gene variant might not confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>In itself, the gene variant was believed not to confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>In itself, the gene variant was not able to confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>In itself, the gene variant will not confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>In itself, the gene variant will not have conferred an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>In itself, the gene variant would not confer an increased risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can have been conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is believed to be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance might be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will have been conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT can confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT can have conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT could confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT has conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT has the ability to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT is able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT is believed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT is observed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT may confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT may have conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT might confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT was able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT was believed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT was observed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT will confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT will have conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT would confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance can be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance could be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance has been conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance is able to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance is believed to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance is conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance may be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance might be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance was able to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance was believed to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance was conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance will be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistance would be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations can confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations conferred the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations could confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations have conferred the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations is able to confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations is believed to confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations may confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations might confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations was able to confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations was believed to confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations will confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations would confer the 06-BG resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistance</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants are believed not to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants are not able to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants cannot confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants could not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants did not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants do not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants have not conferred loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants may not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants might not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants were believed not to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants were not able to confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants will not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>Nonsense or frameshift alterations in the coding sequence or by splice variants would not confer loss-of-function mutations.</text>
                    <arg n="0">nonsense or frameshift alterations in the coding sequence or by splice variants</arg>
                    <arg n="1">loss-of-function mutations</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>Resistance can be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>Resistance can have been conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>Resistance could be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>Resistance has been conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>Resistance has the ability to confer by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>Resistance is able to confer by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>Resistance is conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>Resistance may be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>Resistance may have been conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>Resistance might be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>Resistance was believed to confer by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>Resistance was conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>Resistance will be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>Resistance will have been conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>Resistance would be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, to alkylation chemotherapies.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has been conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by the portion of the STATs</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) might be conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) was believed to be conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>Specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by the portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>That the portion of the STATs can confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>That the portion of the STATs could confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>That the portion of the STATs has conferred specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>That the portion of the STATs has the ability to confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>That the portion of the STATs is able to confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>That the portion of the STATs is believed to confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>That the portion of the STATs may confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>That the portion of the STATs might confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>That the portion of the STATs was able to confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>That the portion of the STATs was believed to confer specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 can confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                    <arg n="M-MOD">can</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 could confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                    <arg n="M-MOD">could</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 has the ability to confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 is able to confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 is believed to confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 may confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 was able to confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since simply replacing the C-terminus with that of Stat5 will confer the Stat5 phenotype of stability in the presence of MG132 on Stat1.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since the Stat5 phenotype of stability in the presence of MG132 can have been conferred on Stat1 by simply replacing the C-terminus with that of Stat5.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                    <arg n="M-MOD">can</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since the Stat5 phenotype of stability in the presence of MG132 could be conferred on Stat1 by simply replacing the C-terminus with that of Stat5.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                    <arg n="M-MOD">could</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since the Stat5 phenotype of stability in the presence of MG132 is able to be conferred on Stat1 by simply replacing the C-terminus with that of Stat5.</text>
                    <arg n="0">simply replacing the C-terminus with that of Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>The portion of the STATs conferred specificity for either a MAPK or a MAPK substrate kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>The portion of the STATs confers specificity for either a MAPK or a MAPK substrate kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>resistance in a tolC-deficient strain can be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>resistance in a tolC-deficient strain has been conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>resistance in a tolC-deficient strain is able to be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>resistance in a tolC-deficient strain is conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>resistance in a tolC-deficient strain may have been conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>resistance in a tolC-deficient strain was conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
